Legal Representation
Attorney
Christopher D. Olszyk, Jr.
USPTO Deadlines
Application History
36 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 20, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Mar 20, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Aug 11, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 9, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 9, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Aug 9, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Feb 5, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 3, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 3, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Feb 3, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Aug 12, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 10, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 10, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Aug 10, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Feb 11, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 9, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 9, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Feb 9, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Aug 11, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 17, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jun 17, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jun 17, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jun 16, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 16, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 27, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 13, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 13, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 13, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 12, 2020 | ALIE | A | ASSIGNED TO LIE |
| May 6, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 30, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 30, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jan 30, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 29, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 30, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 28, 2019 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 001
Diagnostic reagents for clinical or medical laboratory use; diagnostic reagents for scientific or research use; reagents for scientific or medical research use
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Chemical reagents for medical or veterinary purposes; clinical medical reagents; diagnostic reagents for medicinal use; medical diagnostic reagents; reagents for medical use
First Use Anywhere:
0
First Use in Commerce:
0
Class 010
Liquid and tissue biopsy tests and devices, namely, medical instruments for use in performing biopsies and medical diagnostic apparatus for testing biomarkers; cancer screening tests and devices, namely, medical devices for detecting cancer; blood testing apparatus for cancer diagnosis; medical testing devices for tumor diagnosis
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Providing cancer screening services
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Translation
The wording "APERIGEN" has no meaning in a foreign language.
Classification
International Classes
001
005
010
042
044